{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:56:58Z","timestamp":1794023818641,"version":"4.8.0"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2022,9,27]]},"abstract":"\n Importance<\/jats:title>\n Programmed cell death ligand 1 inhibitors combined with chemotherapy has changed the approach to first-line treatment in patients with extensive-stage small cell lung cancer (SCLC). It remained unknown whether adding a programmed cell death 1 (PD-1) inhibitor to chemotherapy provided similar or better benefits in patients with extensive-stage SCLC, which would add evidence on the efficacy of checkpoint inhibitors in the treatment of extensive-stage SCLC.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the efficacy and adverse event profile of the PD-1 inhibitor serplulimab plus chemotherapy compared with placebo plus chemotherapy as first-line treatment in patients with extensive-stage SCLC.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This international, double-blind, phase 3 randomized clinical trial (ASTRUM-005) enrolled patients at 114 hospital sites in 6 countries between September 12, 2019, and April 27, 2021. Of 894 patients who were screened, 585 with extensive-stage SCLC who had not previously received systemic therapy were randomized. Patients were followed up through October 22, 2021.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Patients were randomized 2:1 to receive either 4.5 mg\/kg of serplulimab (n\u2009=\u2009389) or placebo (n\u2009=\u2009196) intravenously every 3 weeks. All patients received intravenous carboplatin and etoposide every 3 weeks for up to 12 weeks.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n The primary outcome was overall survival (prespecified significance threshold at the interim analysis, 2-sided\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.012). There were 13 secondary outcomes, including progression-free survival and adverse events.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among the 585 patients who were randomized (mean age, 61.1 [SD, 8.67] years; 104 [17.8%] women), 246 (42.1%) completed the trial and 465 (79.5%) discontinued study treatment. All patients received study treatment and were included in the primary analyses. As of the data cutoff (October 22, 2021) for this interim analysis, the median duration of follow-up was 12.3 months (range, 0.2-24.8 months). The median overall survival was significantly longer in the serplulimab group (15.4 months [95% CI, 13.3 months-not evaluable]) than in the placebo group (10.9 months [95% CI, 10.0-14.3 months]) (hazard ratio, 0.63 [95% CI, 0.49-0.82];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). The median progression-free survival (assessed by an independent radiology review committee) also was longer in the serplulimab group (5.7 months [95% CI, 5.5-6.9 months]) than in the placebo group (4.3 months [95% CI, 4.2-4.5 months]) (hazard ratio, 0.48 [95% CI, 0.38-0.59]). Treatment-related adverse events that were grade 3 or higher occurred in 129 patients (33.2%) in the serplulimab group and in 54 patients (27.6%) in the placebo group.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Among patients with previously untreated extensive-stage SCLC, serplulimab plus chemotherapy significantly improved overall survival compared with chemotherapy alone, supporting the use of serplulimab plus chemotherapy as the first-line treatment for this patient population.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04063163<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2022.16464","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T11:06:17Z","timestamp":1664276777000},"page":"1223","source":"Crossref","is-referenced-by-count":482,"title":["Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer"],"prefix":"10.1001","volume":"328","author":[{"given":"Ying","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Oncology, Jilin Cancer Hospital, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xuzhou Central Hospital, Xuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Medical Oncology, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Oncology, Jiamusi Cancer Hospital, Jiamusi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilan","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, the First Affiliated Hospital of Nanchang University, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghua","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Oncology, the First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Dvorkin","sequence":"additional","affiliation":[{"name":"Budgetary Healthcare Institution of Omsk Region Clinical Oncology Dispensary, Omsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Linyi Cancer Hospital, Linyi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, the First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsheng","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Cangzhou People\u2019s Hospital, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xicheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuansong","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hematology, China-Japan Union Hospital of Jilin University, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Melkadze","sequence":"additional","affiliation":[{"name":"Academician Fridon Todua Medical Center\u2013Research Institute of Clinical Medicine, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyin","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Oncology, Anhui Provincial Hospital, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhong","family":"Min","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Anhui Chest Hospital, Hefei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maksym","family":"Viguro","sequence":"additional","affiliation":[{"name":"Clinical Research Department, Medical Center Mriya Med-Service, Kryvyi Rih, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingya","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junquan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tangshan People\u2019s Hospital, Tangshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamta","family":"Makharadze","sequence":"additional","affiliation":[{"name":"Department of Oncology-Endocrinology, High Technology Hospital MedCenter LTD, Batumi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterine","family":"Arkania","sequence":"additional","affiliation":[{"name":"LTD Israeli-Georgian Medical Research Clinic Helsicore, Tbilisi, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenying","family":"Kang","sequence":"additional","affiliation":[{"name":"Shanghai Henlius Biotech, Inc, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Shanghai Henlius Biotech, Inc, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Shanghai Henlius Biotech, Inc, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ASTRUM-005 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiubao","family":"Ren","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimer","family":"Kuchava","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoping","family":"Sun","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaofeng","family":"Li","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Lin","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Harputluoglu","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Cicin","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guosheng","family":"Feng","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanrong","family":"Hao","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejing","family":"Ying","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Sun","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihong","family":"Zhong","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyu","family":"An","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Chen","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Yang","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Chen","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Penkov","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriy","family":"Semegen","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Kobziev","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Luo","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiguo","family":"Cao","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiong","family":"Yang","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Fan","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Li","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Mroz","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Akopov","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuncay","family":"Goksel","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmut","family":"Gumus","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlei","family":"Zhuo","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Fang","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Lin","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Hu","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarong","family":"Li","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqun","family":"Zhang","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuwei","family":"Cui","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadezhda","family":"Kovalenko","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cagatay","family":"Arslan","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devrim","family":"Cabuk","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alev","family":"T\u00fcrker","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Bondarenko","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevhen","family":"Hotko","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olexandr","family":"Goloborodko","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongji","family":"Chen","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhao","family":"Wang","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuang","family":"Yu","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junguo","family":"Lu","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Jiang","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xiong","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davit","family":"Giorgadze","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Orlov","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Bilici","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Sinelnikov","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gongyan","family":"Chen","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yue","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhu","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqin","family":"Lu","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Zhvania","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Ulanska","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Lifirenko","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timur","family":"Andabekov","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Smagina","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fedor","family":"Moiseenko","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuksel","family":"Urun","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligong","family":"Nie","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangwei","family":"Cao","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"You","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixin","family":"Huang","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenpeng","family":"Ying","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Tavartkiladze","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariel","family":"Kitiashvili","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amiran","family":"Matitashvili","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsira","family":"Kortua","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugeny","family":"Kulikov","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Cheporov","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Shirinkin","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Ozguroglu","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Artac","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleksii","family":"Kolesnik","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrii","family":"Gardashnikov","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denys","family":"Pominchuk","sequence":"additional","affiliation":[{"name":"for the ASTRUM-005 Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"joi220099r1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer.","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"28","key":"joi220099r3","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1200\/JCO.2009.23.1548","article-title":"Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.","volume":"27","author":"Socinski","year":"2009","journal-title":"J Clin Oncol"},{"issue":"14","key":"joi220099r4","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1200\/JCO.2011.40.4905","article-title":"Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.","volume":"30","author":"Rossi","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"joi220099r5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"joi220099r6","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133).","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"joi220099r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"issue":"21","key":"joi220099r12","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study.","volume":"38","author":"Rudin","year":"2020","journal-title":"J Clin Oncol"},{"key":"joi220099r13","doi-asserted-by":"publisher","first-page":"ix109","DOI":"10.1093\/annonc\/mdz438.007","article-title":"A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy.","volume":"30","author":"Chao","year":"2019","journal-title":"Ann Oncol"},{"key":"joi220099r14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e17510","article-title":"Efficacy and safety evaluation of HLX10 (a recombinant humanized anti-PD-1 monoclonal antibody) combined with albumin-bound paclitaxel in patients with advanced cervical cancer who have progressive disease or intolerable toxicity after first-line standard chemotherapy: a single-arm, open-label, phase 2 study.","volume":"39","author":"Wu","year":"2021","journal-title":"J Clin Oncol"},{"issue":"15","key":"joi220099r15","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1200\/JCO.2021.39.15_suppl.2566","article-title":"Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: a single-arm, multicenter, phase 2 study.","volume":"39","author":"Qin","year":"2021","journal-title":"J Clin Oncol"},{"issue":"23","key":"joi220099r16","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer.","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"30","key":"joi220099r17","doi-asserted-by":"publisher","first-page":"v928","DOI":"10.1093\/annonc\/mdz394.089","article-title":"PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: results from CASPIAN.","author":"Paz-Ares","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"joi220099r18","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.annonc.2021.01.071","article-title":"Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331?.","volume":"32","author":"Spigel","year":"2021","journal-title":"Ann Oncol"},{"issue":"3","key":"joi220099r19","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41416-021-01356-3","article-title":"Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled phase 2 study.","volume":"125","author":"Cheng","year":"2021","journal-title":"Br J Cancer"},{"issue":"2","key":"joi220099r20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jtho.2020.10.002","article-title":"Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): a multicenter, two-stage, phase 2 trial.","volume":"16","author":"Fan","year":"2021","journal-title":"J Thorac Oncol"},{"key":"joi220099r21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.lungcan.2017.11.022","article-title":"Characterization of never-smoking and its association with clinical outcomes in Chinese patients with small-cell lung cancer.","volume":"115","author":"Liu","year":"2018","journal-title":"Lung Cancer"},{"issue":"13","key":"joi220099r22","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1111\/tca.v12.13","article-title":"Survival and pretreatment prognostic factors for extensive-stage small cell lung cancer: a comprehensive analysis of 358 patients.","volume":"12","author":"Huang","year":"2021","journal-title":"Thorac Cancer"},{"issue":"6","key":"joi220099r23","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol"},{"issue":"12","key":"joi220099r25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0257972","article-title":"Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy.","volume":"16","author":"Issafras","year":"2021","journal-title":"PLoS One"},{"issue":"5","key":"joi220099r26","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1097\/JTO.0000000000000146","article-title":"Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer: an analysis of Veterans Health Administration data.","volume":"9","author":"Santana-Davila","year":"2014","journal-title":"J Thorac Oncol"},{"key":"joi220099r2","unstructured":"American Cancer Society. Cancer facts and figures 2021. Accessed January 10, 2022. https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2021.html"},{"key":"joi220099r7","unstructured":"AstraZeneca. Press release: Imfinzi approved in the EU for the treatment of extensive-stage small cell lung cancer. Accessed December 21, 2021. https:\/\/www.astrazeneca.com\/content\/astraz\/media-centre\/press-releases\/2020\/imfinzi-approved-in-EU-for-small-cell-lung-cancer.html"},{"key":"joi220099r8","unstructured":"AstraZeneca. Press release: Imfinzi approved in the US for extensive-stage small cell lung cancer. Accessed December 21, 2021. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2020\/imfinzi-approved-in-the-us-for-extensive-stage-small-cell-lung-cancer.html"},{"key":"joi220099r9","unstructured":"Roche. Press release: FDA approves Roche\u2019s Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer. Accessed December 21, 2021. https:\/\/www.roche.com\/media\/releases\/med-cor-2019-03-19.htm"},{"key":"joi220099r10","unstructured":"Roche. Press release: European Commission approves Roche\u2019s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer. Accessed December 21, 2021. https:\/\/www.roche.com\/media\/releases\/med-cor-2019-09-06b.htm"},{"key":"joi220099r24","unstructured":"Campaign for Tobacco-Free Kids. Global Adult Tobacco Survery: fact sheet China 2018. Accessed July 20, 2022. https:\/\/www.tobaccofreekids.org\/assets\/global\/pdfs\/en\/GATS_China_2018_FactSheet.pdf"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2796691\/jama_cheng_2022_oi_220099_1664218829.26132.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T11:06:26Z","timestamp":1664276786000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2796691"}},"subtitle":["The ASTRUM-005 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,9,27]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2022.16464","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,27]]}}}